(BU) and cyclophosphamide (CY) can cure a high percentage of patients with compatible donors. Little is known about the long-term effects of BMT in patients with thalasThe aim of this study was to evaluate the treatment effects with recombinant human growth hormone semia in relation to the growth process as well as endocrine function. (rhGH) in a group of patients after bone marrow transplantation for thalassemia major. At the end of treat-
diagnosed and graded according to the Seattle criteria.
1 ner et al. 4 The secondary sex characteristic development was evaluated by the Tanner and Whitehouse pubertal Details of the marrow grafting procedure and management of the patients after grafting have been described elsedevelopment standards for breast, pubic hair and genital maturity. 5 where.
2
Growth velocity (GV) expressed in cm/year was calculated for at least 6 months before treatment at the end of Auxologic evaluation therapy annually. GV data were converted to standard deviation score (SDSGV). Height determinations were performed using a Harpenden stadiometer according to the criteria of Tanner. 3 Height data Predicted adult height (PAH) was calculated by the Tanner-Whitehouse II method 4 and Bayley-Pinneau method were converted to standard deviation score for the chronological age (hSDS) and for the bone age (hSDSBA). Bone (BP). 6 The genetic target height (TH) was calculated from the average parental height plus 5.5 cm for the boys and age (BA) was estimated by a single observer from radiographs of the left hand and wrist using the method of Tanminus 5.5 cm for the girls. Parental height standard deviation score was also calculated.
Blood analysis
GH levels were evaluated during two consecutive stimuli tests on samples obtained at 0, 30, 60, 90 and 120 min following the administration of clonidine (150 g/m 2 ) orally. Serum GH levels were measured in duplicate by an immunoradiometric assay (hGH-CTK-IRMA) (Sorin Biomedica, Milan, Italy). The sensitivity of the assay was 0.15 g/l. The ranges of inter-and intra-assay coefficients of variation were 4.9-6.5%, respectively. The maximum GH serum concentration observed (max) and the time of its occurrence (T max ) were obtained from individual data. All patients underwent priming with sex steroids prior to GH stimulation tests. For priming we utilised 100 mg i.m. testosterone esters for 7 days before GH stimulation test in boys 10 years or older. Ethinyl estradiol 50 g was administered orally for 3 days prior to GH stimulation test in girls 9 years or older. Girls whose bone age is less than 9 and boys whose bone age is less than 10 years do not need priming. Values were expressed as nanograms per millilitre.
All patients had GH peaks Ͻ4 ng/ml. Plasma IGF-I values (ng/ml) were determined using a commercial kit (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA) that encloses an acid chromatogra- 18 Sep-pak; Millipore, Waters Associates, Bedford, MA, USA). Each sample was assayed in duplicate. The sensitivity of the method was 0.06 g/l and the intra-and interassay coefficients of variation were 2.85 and 10.21%, respectively. Serum aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) (IU/l) were determined with standard methods. Serum ferritin levels (ng/ml) were assessed by radioimmunoassay. Thyroid stimulating hormone (TSH), thyronine (T3) with free fraction (FT3) and thyroxine (T4) with free fraction (FT4) were also evaluated.
A standard oral glucose tolerance test (OGTT: 1.75 g glucose/kg, up to 75 g) was performed in all patients before and during therapy at 6 monthly intervals. The tests were started between 8.00 am and 9.00 am and blood was drawn during intervals of 0, 30, 60, 90, 120 and 180 min. Plasma glucose levels (g/l) were measured by an enzymatic method using the Beckman (Palo Alto, CA, USA) glucose analyser. Plasma insulin (IU/ml) was assessed by a double antibody radioimmunoassay.
All patients were tested for HCV-RNA. Hepatic biopsy was performed in only five patients.
Statistical analysis
Auxologic data are presented in absolute single values and as mean ± s.d. Metabolic data were expressed as means ± s.d.
We utilised Student's t-test and a simple linear regression was used to analyse the relationship between IGF-I, SGOT, SGPT and ferritin. The simple linear regression was also used for the correlations between hSDS and predicted adult height. In Table 1 , the physical characteristics of the patients before and at the end of the rhGH treatment are represented. hSDS = Height standard deviation score; BA = bone age; hSDSBA = hSDS for bone age; SDSGV = standard deviation score of the growth velocity. *P = 0.01; **P = 0.0001; NS = not significant.
Responder group Non-responder group
These patients had a worsening of hSDS, hSDSBA and At the start of therapy four patients (three boys, one girl) presented Tanner's pubertal stage I. The boys had testicular SDSGV during rhGH administration (hSDS: −3.60 ± 1.13 vs −4.85 ± 0.49, P = NS; hSDSBA: −1.95 ± 0.92 vs −2.20 volumes Ͻ3 ml. Only one patient (case 4) presented stage II with testicular volume of 4 ml. At the end of treatment ± 0.28, P = NS, SDSGV: −4.20 ± 0.57 vs −5.70 ± 0.71, P = NS (Table 1 and Figure 1 ). There was no significant the one patient that reached stage II progressed to stage III with testicular volume of 7 ml. After 24 months of rhGH difference probably due to the small sample. No signs of pubertal development were observed during administration, growth rate was still significantly higher than at the start of treatment (1.66 ± 0.68 vs 7.54 2 years of therapy in these patients. There was no increase of the IGF-I levels: ± 1.64 cm/year, P Ͻ 0.0001) ( Table 1) . Figure 1 shows the means and s.d. of SDSGV, hSDS and 20.75 ± 1.06 vs 36.7 ± 11.0, P = NS (Table 2) . Single values of the serum transaminase and ferritin levhSDSBA (the single values for each patient are shown in Table 1 ). The mean of SDSGV increased significantly from els were higher than in responder patients (Table 2) Table 2 ). In Figure 2 glucose and insulin values during OGTT are ± 0.37 (P = NS).
Prior to the treatment the CA/BA ratio was 1.13 ± 0.08, shown. No significant difference was found during the treatment. at 24 months after therapy it was 1.05 ± 0.13 (P = NS) ( Table 1) .
In Figure 3 the significant correlation between IGF-I, SGOT, SGPT and ferritin is displayed (r = −0.462, Table 2 shows single values and means respectively of IGF-I, transaminase and ferritin before and after therapy. P Ͻ 0.01; r = −0.476, P Ͻ 0.01; r = −0.563, P Ͻ 0.05, respectively). Plasma levels of IGF-I rose significantly from values of 45.04 ± 20.86 to 162.8 ± 21.81 ng/ml (P Ͻ 0.003).
All patients had normal thyroid function. Parental height SDS, TH SDS and hSDS corrected for The serum levels of SGOT, SGPT and ferritin were higher compared to normal values but improved in non-TH, for each patient, are listed in Table 3 ; PAH are also shown. responder patients. There was no difference in the mean concentrations of these parameters before and after treatFinal PAH (expressed as SDS) significantly increased in responder patients after treatment (TW2: −1.92 ± 0.66 ment: SGOT 43.0 ± 23.71 vs 30.0 ± 18.8 IU/l (P = NS); SGPT 37.2 ± 15.1 vs 32.0 ± 19.31 IU/l (P = NS); ferritin vs −1.06 ± 0.29, P Ͻ 0.05; BP: −2.06 ± 0.46 vs −1.10 ± 0.42, P Ͻ 0.001) and hSDS corrected for TH surpassed 847 ± 612 vs 533.4 ± 243.66 ng/ml (P = NS). even the TH. In non-responders there was a worsening of major treated with conventional therapy consisting of transfusion and chelation. Several factors have been identified the final PAH (TW2: −1.90 ± 0.99 vs −2.25 ± 0.35 P = NS; BP: −2.60 ± 0.49 vs −3.0 ± 0.85 P = NS) and hSDS coras being responsible for these complications: deranged function of the hypothalamic-pituitary-gonadal axis, [7] [8] [9] [10] [11] [12] [13] rected for TH improved with respect to the TH (Figure 4) . abnormal hepatic conversion of steroid hormones to their active metabolites 14 and defective hepatic biosynthesis of insulin-like growth factor (IGF-1). 15 It is possible that iron Discussion overload is primarily involved in this phenomenon. Chronically transfused, inadequately chelated patients develop Growth retardation and delayed or absent sexual maturation are still a common observation in children with thalassemia hepatocellular injury and late growth failure within the first decade of life. This is followed in adolescence by pubertal patients who received BU-CY or, alternatively, CY/total body irradiation. 27 failure and dysfunctions of various endocrine organs. Although the long-term efficacy of rhGH treatment can Allogeneic BMT represents the only possible cure for only be assessed at adult height, we have evaluated the patients with thalassemia major if an HLA-identical sibling predicted adult height for our patients before and after therdonor is available. 2, 16, 17 In order to eradicate underlying apy. Final predicted adult height (TW2 and BP methods) hematological disorder and to suppress the patient's increase in responders at end of treatment. These two immune system, all patients receive high doses of BU and methods did not give discordant predictions. Although in CY. It is of interest to ascertain the late effects of this treatthese patients several factors seem to control the adult ment modality on the child's subsequent growth and puberheight, we do not believe that the predicted adult height tal development, as well as the possible benefits of transwas overestimated given that the hSDS corrected for genfusion therapy elimination.
etic [21] [22] [23] or a reduced spontaneous GH showed a growth improvement in non-transplanted thalassecretion all day with a low number of pulses and reduced semic patients submitted to long-term treatment with rhGH. mean pulse amplitude. 24 In short-stature patients with norIn conclusion, these results are encouraging. Daily rhGH mal GH response to provocative stimulation tests, abnormal administration, at a weekly dose of 0.9 IU/kg for 24 conpulsatile GH secretion has been reported (neurosecretory secutive months, has been proven to be a safe and effidysfunction). 25 cacious drug in promoting linear growth in GH-deficient However, definite data about GH secretion in transtransplanted thalassemic patients. This treatment can offer planted thalassemic patients are lacking in the literature.
good results only in cases where the hepatic synthesis of Our previous study, 26 conducted in thalassemic patients IGF-I is conserved and liver damage is not irreversible, as submitted to BMT, showed that the GH secretion was observed in our responder group. Naturally, as in all new blunted in 59.09% of the subjects examined and demontherapeutic attempts with this hormone, even in different strated a close correlation between the patient's age at time conditions, only the final adult height will permit us to of BMT and subsequent growth rate. The patients whose judge the effectiveness of the treatment in correlation to age at transplant was Ͻ7 years had a less impaired growth the genetic target height. rate than patients who were Ͼ7 years. This suggests that the duration of the disease may be an important factor regarding the defect in GH secretion and in IGF-I proReferences duction related to liver damage.
Data from this study showed that the administration of In non-responders (2/7) patients growth worsened and
